Effective targeting of primitive AML CD34+cells by the second-generation proteasome inhibitor carfilzomib

The TAK1-NF- B axis as therapeutic target for AML

(2014) M. C. J. Bosman et al.   BLOOD

Positive feedback between NF-κB and TNF-α promotes leukemia-initiating cell capacity

(2014) Yuki Kagoya et al.   JOURNAL OF CLINICAL INVESTIGATION

Carfilzomib

(2013) K. M. Kortuem et al.   BLOOD

Targeting the ubiquitin proteasome system in haematological malignancies

(2013) Lisa J. Crawford et al.   BLOOD REVIEWS

Targeting IRAK1 as a Therapeutic Approach for Myelodysplastic Syndrome

(2013) Garrett W. Rhyasen et al.   CANCER CELL

Bortezomib sensitivity of acute myeloid leukemia CD34+ cells can be enhanced by targeting the persisting activity of NF-κB and the accumulation of MCL-1

(2013) Matthieu Cornelis Johannes Bosman et al.   EXPERIMENTAL HEMATOLOGY

A Proteomics and Transcriptomics Approach to Identify Leukemic Stem Cell (LSC) Markers

(2012) Francesco Bonardi et al.   MOLECULAR & CELLULAR PROTEOMICS

Proteasome Enzymatic Activities in Plasma as Risk Stratification of Patients with Acute Myeloid Leukemia and Advanced-Stage Myelodysplastic Syndrome

(2009) W. Ma et al.   CLINICAL CANCER RESEARCH